Sarepta Therapeutics (SRPT) PT Lowered to $150 but Needham & Company Offers 4 Reasons to be Bullish into the 2-Year Update
Tweet Send to a Friend
Needham & Company analyst Chad Messer lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $150.00 (from $157.00) but ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
